Boston Scientific: Sustained Outperformance and Solid Growth Support Buy Rating Despite Trimmed Target

Michael Matson, an analyst from Needham, maintained the Buy rating on Boston Scientific. The associated price target was lowered to $77.00.

Michael Matson has given his Buy rating due to a combination of factors including Boston Scientific’s continued revenue and EPS outperformance versus consensus despite a reset in 2026 guidance. He notes that while organic growth moderated in the first quarter as FARAPULSE and WATCHMAN expansion decelerated and Urology and CRM encountered operational pressures, overall growth remains solid on an absolute basis and above many peers.

Looking ahead, Matson acknowledges that management anticipates further slowing in FARAPULSE and WATCHMAN but expects stabilization and improvement in Urology and CRM to partially offset these headwinds. He also factors in the temporary nature of gross margin pressure from tariffs and POLARx inventory charges, and while he meaningfully trims his price target to $77 from $97 to reflect a more conservative growth and margin trajectory, he still sees attractive upside from current levels, which supports maintaining a Buy recommendation.

In another report released today, Barclays also maintained a Buy rating on the stock with a $100.00 price target.